Title :

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up

Author(s) :

Colombat, P. [Auteur]
Service d'hématologie [Tours]
Brousse, N. [Auteur]
Salles, G. [Auteur]
Morschhauser, Franck [Auteur]
Hôpital Claude Huriez [Lille]
Brice, P. [Auteur]
Soubeyran, P. [Auteur]
Delwail, V. [Auteur]
Deconinck, E. [Auteur]
Haioun, C. [Auteur]
Foussard, C. [Auteur]
Sebban, C. [Auteur]
Tilly, H. [Auteur]
Thieblemont, C. [Auteur]
Bergougnoux, L. [Auteur]
Lazreg, F. [Auteur]
Solal-Celigny, P. [Auteur]

Journal title :

Annals of Oncology

Abbreviated title :

Ann. Oncol.

Volume number :

23

Pages :

2380-2385

Publication date :

2015-07-11

ISSN :

0923-7534

English keyword(s) :

rituximab
low-burden
induction monotherapy
follicular lymphoma

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). Patients and methods Of 49 first-line LTBFL patients ...
Show more >Background The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). Patients and methods Of 49 first-line LTBFL patients who received weekly doses of rituximab (375 mg/m2), 46 have been followed with a long-term analysis of clinical and molecular responses. Results Best clinical response (at any staging within a year following treatment) was 80%, 24 (52%) patients had complete or unconfirmed complete response, 13 (28%) had partial response and 9 (20%) had stable or progressive disease. Of 31 patients having a positive bcl2-JH rearrangement, 15 (48%) became negative following treatment. After 83.9 months of follow-up (95% confidence interval 6.4–92.8 months), the median progression-free survival is 23.5 months and overall survival (OS) is 91.7%. Five patients died (one progression, one myelodysplasia, one diffuse large B-cell lymphoma and two solid tumors). Seven patients (15%) are progression-free including five who are bcl2 informative. No unexpected long-term adverse event has been observed. Conclusion A significant proportion of patients remain progression-free 7 years after a single 4-dose rituximab treatment in first-line LTBFL. The 7-year overall survivalOS is very high in this selected population of patients.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Submission date :

2023-05-25T03:40:50Z
2024-06-19T11:14:08Z